Zealand Pharma
Zealand Pharma and OTR Therapeutics in multi-program strategic collaboration for metabolic diseases
Zealand Pharma; OTR Therapeutics; strategic collaboration; license agreement; metabolic diseases; obesity; oral small-molecule therapeutics; R&D partnership; China biotech; upfront payment; milestone payments; royalties
Zealand Pharma Pauses Development of GLP-1/GLP-2 Dual Agonist Dapiglutide for Obesity
Zealand Pharma; dapiglutide; GLP-1/GLP-2 dual agonist; obesity therapy; clinical development; obesity drug market; pipeline management; petrelintide; survodutide
Zealand Pharma’s Dual GLP-1/GLP-2 Agonist Dapiglutide Shows Promising 11.6% Weight Loss at 28 Weeks
Zealand Pharma; dapiglutide; GLP-1; GLP-2; weight loss; obesity; phase 1b trial; clinical trial; dual agonist; safety
FDA Issues Complete Response Letter for Zealand Pharma’s Glepaglutide in Short Bowel Syndrome Treatment
Zealand Pharma, Glepaglutide, GLP-2 analog, Short Bowel Syndrome (SBS), FDA rejection, Complete Response Letter
FDA Delays Approval of Zealand Pharma’s Dasiglucagon for Congenital Hyperinsulinism Due to Third-Party Manufacturing Issues
Zealand Pharma, dasiglucagon, congenital hyperinsulinism, FDA, Complete Response Letter, third-party manufacturing issues
Zealand’s Hypoglycemia Drug Faces Second FDA Rejection Due to Manufacturing Issues
Zealand Pharma, FDA rejection, dasiglucagon, congenital hyperinsulinism, hypoglycemia, CDMO inspection
Zealand Pharma’s GLP-1/GLP-2 Receptor Dual Agonist Shows Promising Weight Loss in Phase 1b Trial
Zealand Pharma, GLP-1/GLP-2 receptor dual agonist, dapiglutide, obesity, weight loss, Phase 1b trial
Zealand Raises $1 Billion to Advance Amylin Obesity Drug and Seek Partnership
Zealand Pharma, Obesity, Amylin, Weight Loss, $1 Billion Raise, Partnership